Allarity Therapeutics, Inc. is a clinical-stage, precision medicine pharmaceutical company. It is advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its clinical program includes three anti-cancer assets in mid-stage clinical development and one anti-cancer asset in early-stage clinical development. Its programs and partnerships leverage its Drug Response Predictor technology to refine patient selection and improve clinical outcomes. It is focused on clinical development of three programs: dovitinib in combination with stenoparib for the second-line or later treatment of metastatic ovarian cancer; stenoparib as a monotherapy for ovarian cancer, and IXEMPRA as a monotherapy for metastatic breast cancer. Its dovitinib is a selective inhibitor of several classes of tyrosine kinases, including FGFR and VEGFR. Its IXEMPRA is a selective microtubule inhibitor, which has been shown to interfere with cancer cell division, to cell death.